242 related articles for article (PubMed ID: 34070642)
21. Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids.
Marchetti M; Liuzzi A; Fermi B; Corsini R; Folli C; Speranzini V; Gandolfi F; Bettati S; Ronda L; Cendron L; Berni R; Zanotti G; Percudani R
Sci Rep; 2016 Dec; 6():38302. PubMed ID: 27922051
[TBL] [Abstract][Full Text] [Related]
22. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Wu X; Wakamiya M; Vaishnav S; Geske R; Montgomery C; Jones P; Bradley A; Caskey CT
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):742-6. PubMed ID: 8290593
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of a novel bacterial sulfite oxidase with no heme binding domain from Deinococcus radiodurans.
D'Errico G; Di Salle A; La Cara F; Rossi M; Cannio R
J Bacteriol; 2006 Jan; 188(2):694-701. PubMed ID: 16385059
[TBL] [Abstract][Full Text] [Related]
24. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
25. Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice.
Pierzynowska K; Deshpande A; Mosiichuk N; Terkeltaub R; Szczurek P; Salido E; Pierzynowski S; Grujic D
Front Med (Lausanne); 2020; 7():569215. PubMed ID: 33330529
[TBL] [Abstract][Full Text] [Related]
26. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K; Scheinfeld N
Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
[TBL] [Abstract][Full Text] [Related]
27. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
28. [Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].
Soós B; Szamosi S; Benkő S; Paragh G; Szekanecz Z
Orv Hetil; 2018 Oct; 159(40):1625-1636. PubMed ID: 30277413
[TBL] [Abstract][Full Text] [Related]
29. A widely distributed gene cluster compensates for uricase loss in hominids.
Liu Y; Jarman JB; Low YS; Augustijn HE; Huang S; Chen H; DeFeo ME; Sekiba K; Hou BH; Meng X; Weakley AM; Cabrera AV; Zhou Z; van Wezel G; Medema MH; Ganesan C; Pao AC; Gombar S; Dodd D
Cell; 2023 Aug; 186(16):3400-3413.e20. PubMed ID: 37541197
[TBL] [Abstract][Full Text] [Related]
30. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Terkeltaub R; Bushinsky DA; Becker MA
Arthritis Res Ther; 2006; 8 Suppl 1(Suppl 1):S4. PubMed ID: 16820043
[TBL] [Abstract][Full Text] [Related]
31. [Gout and cardiovascular risk].
Němec P
Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
[TBL] [Abstract][Full Text] [Related]
32. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
Lu J; Hou X; Yuan X; Cui L; Liu Z; Li X; Ma L; Cheng X; Xin Y; Wang C; Zhang K; Wang X; Ren W; Sun R; Jia Z; Tian Z; Mi QS; Li C
Kidney Int; 2018 Jan; 93(1):69-80. PubMed ID: 28729031
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
34. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach.
Tripathi S; Parmar J; Kumar A
Protein J; 2020 Apr; 39(2):133-144. PubMed ID: 32221804
[TBL] [Abstract][Full Text] [Related]
36. Urate oxidase (rasburicase) for treatment of severe tophaceous gout.
Vogt B
Nephrol Dial Transplant; 2005 Feb; 20(2):431-3. PubMed ID: 15673692
[No Abstract] [Full Text] [Related]
37. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
[TBL] [Abstract][Full Text] [Related]
38. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
39. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
40. Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.
Pfrimer P; de Moraes LM; Galdino AS; Salles LP; Reis VC; De Marco JL; Prates MV; Bloch C; Torres FA
J Biomed Biotechnol; 2010; 2010():674908. PubMed ID: 20168977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
